Lumos Diagnostics rises on interim nod for COVID test in Canada

Lumos Diagnostics Holdings

27/06/2022 03:18

** Shares of diagnostics solution provider Lumos Diagnostics
Holdings  LDX.AX  rise as much as 16% to A$0.145
    ** Stock on track for the best session since March 21, if
gains hold
    ** Co receives https://www.asx.com.au/asxpdf/20220627/pdf/45b8bv4zdhnns5.pdf
 Interim Order authorisation from Health Canada for its ViraDx
three-in-one antigen test for COVID-19, Flu A and Flu B in
Canada
    ** ViraDx is currently under review by the U.S. Food and
Drug Administration for Emergency Use Authorisation
    ** As of last close, LDX down ~86.6% so far this year

 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))